Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Prescribing quality in secondary care patients with different stages of chronic kidney disease: a retrospective study in the Netherlands.

Smits KP, Sidorenkov G, van Ittersum FJ, Waanders F, Bilo HJ, Navis GJ, Denig P.

BMJ Open. 2019 Jul 19;9(7):e025784. doi: 10.1136/bmjopen-2018-025784.

2.

Ethnic Differences in the Association of Depressive Symptoms with Clinical Outcome in Dialysis Patients.

Schouten RW, Haverkamp GL, Loosman WL, Chandie Shaw PK, van Ittersum FJ, Smets YFC, Vleming LJ, Dekker FW, Honig A, Siegert CEH.

J Racial Ethn Health Disparities. 2019 Jun 18. doi: 10.1007/s40615-019-00600-0. [Epub ahead of print]

PMID:
31215016
3.

Antibodies against ARHGDIB are associated with long-term kidney graft loss.

Kamburova EG, Gruijters ML, Kardol-Hoefnagel T, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas MC, Spierings E, Hack CE, van Reekum FE, van Zuilen AD, Verhaar MC, Bots ML, Drop ACAD, Plaisier L, Melchers RCA, Seelen MAJ, Sanders JS, Hepkema BG, Lambeck AJA, Bungener LB, Roozendaal C, Tilanus MGJ, Voorter CE, Wieten L, van Duijnhoven EM, Gelens MACJ, Christiaans MHL, van Ittersum FJ, Nurmohamed SA, Lardy NM, Swelsen W, van der Pant KAMI, van der Weerd NC, Ten Berge IJM, Hoitsma A, van der Boog PJM, de Fijter JW, Betjes MGH, Heidt S, Roelen DL, Claas FH, Bemelman FJ, Otten HG.

Am J Transplant. 2019 Jun 13. doi: 10.1111/ajt.15493. [Epub ahead of print]

PMID:
31194283
4.

Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients.

Heidt S, Haasnoot GW, Witvliet MD, van der Linden-van Oevelen MJH, Kamburova EG, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas MC, Spierings E, Hack CE, van Reekum FE, van Zuilen AD, Verhaar MC, Bots ML, Drop ACAD, Plaisier L, Seelen MAJ, Sanders JS, Hepkema BG, Lambeck AJA, Bungener LB, Roozendaal C, Tilanus MGJ, Voorter CE, Wieten L, van Duijnhoven EM, Gelens MACJ, Christiaans MHL, van Ittersum FJ, Nurmohamed SA, Lardy NM, Swelsen W, van der Pant KAMI, van der Weerd NC, Ten Berge IJM, Bemelman FJ, Hoitsma A, van der Boog PJM, de Fijter JW, Betjes MGH, Otten HG, Roelen DL, Claas FHJ.

Am J Transplant. 2019 Jun 2. doi: 10.1111/ajt.15486. [Epub ahead of print]

PMID:
31155833
5.

Anxiety Symptoms, Mortality, and Hospitalization in Patients Receiving Maintenance Dialysis: A Cohort Study.

Schouten RW, Haverkamp GL, Loosman WL, Chandie Shaw PK, van Ittersum FJ, Smets YFC, Vleming LJ, Dekker FW, Honig A, Siegert CEH.

Am J Kidney Dis. 2019 Apr 23. pii: S0272-6386(19)30619-5. doi: 10.1053/j.ajkd.2019.02.017. [Epub ahead of print]

6.

Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients.

Kamburova EG, Kardol-Hoefnagel T, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas MC, Spierings E, Hack CE, van Reekum FE, van Zuilen AD, Verhaar MC, Bots ML, Drop ACAD, Plaisier L, Meeldijk J, Bovenschen N, Seelen MAJ, Sanders JS, Hepkema BG, Lambeck AJA, Bungener LB, Roozendaal C, Tilanus MGJ, Voorter CE, Wieten L, van Duijnhoven EM, Gelens MACJ, Christiaans MHL, van Ittersum FJ, Nurmohamed SA, Lardy NM, Swelsen W, van der Pant KAMI, van der Weerd NC, Ten Berge IJM, Bemelman FJ, van der Boog PJM, de Fijter JW, Betjes MGH, Heidt S, Roelen DL, Claas FH, Otten HG.

Front Immunol. 2018 Dec 19;9:3002. doi: 10.3389/fimmu.2018.03002. eCollection 2018.

7.

Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients.

Michielsen LA, van Zuilen AD, Verhaar MC, Wisse BW, Kamburova EG, Joosten I, Allebes WA, van der Meer A, Baas MC, Spierings E, Hack CE, van Reekum FE, Bots ML, Drop ACAD, Plaisier L, Seelen MAJ, Sanders JF, Hepkema BG, Lambeck AJ, Bungener LB, Roozendaal C, Tilanus MGJ, Voorter CE, Wieten L, van Duijnhoven EM, Gelens MACJ, Christiaans MHL, van Ittersum FJ, Nurmohamed SA, Lardy NM, Swelsen W, van der Pant KA, van der Weerd NC, Ten Berge IJM, Bemelman FJ, Hoitsma A, van der Boog PJM, de Fijter JW, Betjes MGH, Heidt S, Roelen DL, Claas FH, Otten HG, Hilbrands LB.

Nephrol Dial Transplant. 2018 Dec 15. doi: 10.1093/ndt/gfy377. [Epub ahead of print]

PMID:
30561730
8.

Impaired nocturnal blood pressure dipping in patients with type 2 diabetes mellitus.

Kim YS, Davis SCAT, Stok WJ, van Ittersum FJ, van Lieshout JJ.

Hypertens Res. 2019 Jan;42(1):59-66. doi: 10.1038/s41440-018-0130-5. Epub 2018 Nov 6.

PMID:
30401911
9.

A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.

Michielsen LA, Wisse BW, Kamburova EG, Verhaar MC, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas MC, Spierings E, Hack CE, van Reekum FE, Bots ML, Drop ACAD, Plaisier L, Seelen MAJ, Sanders JF, Hepkema BG, Lambeck AJ, Bungener LB, Roozendaal C, Tilanus MGJ, Voorter CE, Wieten L, van Duijnhoven EM, Gelens M, Christiaans MHL, van Ittersum FJ, Nurmohamed SA, Lardy NM, Swelsen W, van der Pant KA, van der Weerd NC, Ten Berge IJM, Bemelman FJ, Hoitsma A, van der Boog PJM, de Fijter JW, Betjes MGH, Heidt S, Roelen DL, Claas FH, Otten HG, van Zuilen AD.

Nephrol Dial Transplant. 2019 Jun 1;34(6):1056-1063. doi: 10.1093/ndt/gfy316.

PMID:
30365008
10.

Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival.

Wisse BW, Kamburova EG, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas MC, Spierings E, Hack CE, van Reekum FE, van Zuilen AD, Verhaar MC, Bots ML, Drop ACAD, Plaisier L, Seelen MAJ, Stephan Sanders J, Hepkema BG, Lambeck AJA, Bungener LB, Roozendaal C, Tilanus MGJ, Voorter CE, Wieten L, van Duijnhoven EM, Gelens MACJ, Christiaans MHL, van Ittersum FJ, Nurmohamed SA, Lardy NM, Swelsen W, van der Pant KAMI, van der Weerd NC, Ten Berge IJM, Bemelman FJ, Hoitsma AJ, van der Boog PJM, de Fijter JW, Betjes MGH, Heidt S, Roelen DL, Claas FH, Otten HG.

Transplantation. 2019 Apr;103(4):789-797. doi: 10.1097/TP.0000000000002357.

11.

Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure.

Kamburova EG, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas MC, Spierings E, Hack CE, van Reekum FE, van Zuilen AD, Verhaar MC, Bots ML, Drop ACAD, Plaisier L, Seelen MAJ, Sanders JS, Hepkema BG, Lambeck AJA, Bungener LB, Roozendaal C, Tilanus MGJ, Voorter CE, Wieten L, van Duijnhoven EM, Gelens MACJ, Christiaans MHL, van Ittersum FJ, Nurmohamed SA, Lardy NM, Swelsen W, van der Pant KAMI, van der Weerd NC, Ten Berge IJM, Bemelman FJ, Hoitsma AJ, van der Boog PJM, de Fijter JW, Betjes MGH, Heidt S, Roelen DL, Claas FH, Otten HG.

J Am Soc Nephrol. 2018 Sep;29(9):2279-2285. doi: 10.1681/ASN.2018020205. Epub 2018 Jul 26.

PMID:
30049681
12.

Routine hemodialysis induces a decline in plasma magnesium concentration in most patients: a prospective observational cohort study.

Leenders NHJ, van Ittersum FJ, Hoekstra T, Hoenderop JGJ, Vervloet MG.

Sci Rep. 2018 Jul 6;8(1):10256. doi: 10.1038/s41598-018-28629-x.

13.

Differences in peritoneal response after exposure to low-GDP bicarbonate/lactate-buffered dialysis solution compared to conventional dialysis solution in a uremic mouse model.

Vila Cuenca M, Keuning ED, Talhout W, Paauw NJ, van Ittersum FJ, Ter Wee PM, Beelen RHJ, Vervloet MG, Ferrantelli E.

Int Urol Nephrol. 2018 Jun;50(6):1151-1161. doi: 10.1007/s11255-018-1872-3. Epub 2018 May 4.

14.

PIRCHE-II Is Related to Graft Failure after Kidney Transplantation.

Geneugelijk K, Niemann M, Drylewicz J, van Zuilen AD, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas MC, Hack CE, van Reekum FE, Verhaar MC, Kamburova EG, Bots ML, Seelen MAJ, Sanders JS, Hepkema BG, Lambeck AJ, Bungener LB, Roozendaal C, Tilanus MGJ, Vanderlocht J, Voorter CE, Wieten L, van Duijnhoven EM, Gelens M, Christiaans MHL, van Ittersum FJ, Nurmohamed A, Lardy JNM, Swelsen W, van der Pant KA, van der Weerd NC, Ten Berge IJM, Bemelman FJ, Hoitsma A, van der Boog PJM, de Fijter JW, Betjes MGH, Heidt S, Roelen DL, Claas FH, Otten HG, Spierings E.

Front Immunol. 2018 Mar 5;9:321. doi: 10.3389/fimmu.2018.00321. eCollection 2018.

15.

Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant.

Kamburova EG, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas MC, Spierings E, Hack CE, van Reekum FE, van Zuilen AD, Verhaar MC, Bots ML, Drop ACAD, Plaisier L, Seelen MAJ, Sanders JSF, Hepkema BG, Lambeck AJA, Bungener LB, Roozendaal C, Tilanus MGJ, Voorter CE, Wieten L, van Duijnhoven EM, Gelens M, Christiaans MHL, van Ittersum FJ, Nurmohamed SA, Lardy NM, Swelsen W, van der Pant KA, van der Weerd NC, Ten Berge IJM, Bemelman FJ, Hoitsma A, van der Boog PJM, de Fijter JW, Betjes MGH, Heidt S, Roelen DL, Claas FH, Otten HG.

Am J Transplant. 2018 Sep;18(9):2274-2284. doi: 10.1111/ajt.14709. Epub 2018 Apr 16.

16.

Effects of Oral Paricalcitol and Calcitriol Treatment on Peritoneal Membrane Characteristics of Peritoneal Dialysis Patients - A Pilot Study.

Farhat K, Stavenuiter AWD, Vervloet MG, Ter Wee PM, Beelen RHJ, van Ittersum FJ.

Perit Dial Int. 2018 May-Jun;38(3):220-228. doi: 10.3747/pdi.2017.00150. Epub 2018 Jan 31.

PMID:
29386308
17.

Effluent and serum protein N-glycosylation is associated with inflammation and peritoneal membrane transport characteristics in peritoneal dialysis patients.

Ferrantelli E, Farhat K, Ederveen ALH, Reiding KR, Beelen RHJ, van Ittersum FJ, Wuhrer M, Dotz V.

Sci Rep. 2018 Jan 17;8(1):979. doi: 10.1038/s41598-018-19147-x.

18.

Initiation of peritoneal dialysis in the first weeks after catheter insertion: A comparison of a neutral-pH, low-GDP PD fluid and a conventional PD fluid
.

Farhat K, van Ittersum FJ, Ter Wee PM, Paauw NJ, Beelen RHJ, Douma CE.

Clin Nephrol. 2018 Feb;89(2):75-82. doi: 10.5414/CN109037.

PMID:
28992851
19.

Prediction models for the mortality risk in chronic dialysis patients: a systematic review and independent external validation study.

Ramspek CL, Voskamp PW, van Ittersum FJ, Krediet RT, Dekker FW, van Diepen M.

Clin Epidemiol. 2017 Sep 5;9:451-464. doi: 10.2147/CLEP.S139748. eCollection 2017.

20.

Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.

Farhat K, Douma CE, Ferrantelli E, Ter Wee PM, Beelen RHJ, van Ittersum FJ.

Perit Dial Int. 2017 May-Jun;37(3):273-282. doi: 10.3747/pdi.2015.00031. Epub 2017 Mar 27.

PMID:
28348100
21.

Improved Outcome of Enteric Peritonitis in Peritoneal Dialysis Patients Aged 50 Years and Older with Temporary Discontinuation of Peritoneal Dialysis and Intravenous Meropenem.

Abrahams AC, Rüger W, Ter Wee PM, van Ittersum FJ, Boer WH.

Perit Dial Int. 2017 May-Jun;37(3):298-306. doi: 10.3747/pdi.2016.00147. Epub 2017 Jan 17.

PMID:
28096441
22.

Development and initial validation of prescribing quality indicators for patients with chronic kidney disease.

Smits KP, Sidorenkov G, Bilo HJ, Bouma M, van Ittersum FJ, Voorham J, Navis G, Denig P.

Nephrol Dial Transplant. 2016 Nov;31(11):1876-1886. Epub 2016 Jan 6.

PMID:
26743176
23.

Increased risk of graft failure and mortality in Dutch recipients receiving an expanded criteria donor kidney transplant.

van Ittersum FJ, Hemke AC, Dekker FW, Hilbrands LB, Christiaans MH, Roodnat JI, Hoitsma AJ, van Diepen M.

Transpl Int. 2017 Jan;30(1):14-28. doi: 10.1111/tri.12863.

24.

How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?

Kamburova EG, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas MC, Spierings E, Hack CE, van Reekum FE, van Zuilen AD, Verhaar M, Bots ML, Drop AC, Plaisier L, Seelen MA, Sanders JS, Hepkema BG, Lambeck AJ, Bungener LB, Roozendaal C, Tilanus MG, Vanderlocht J, Voorter CE, Wieten L, van Duijnhoven EM, Gelens M, Christiaans MH, van Ittersum FJ, Nurmohamed A, Lardy NM, Swelsen W, van der Pant KA, van der Weerd NC, Ten Berge IJ, Bemelman FJ, Hoitsma A, van der Boog PJ, de Fijter JW, Betjes MG, Heidt S, Roelen DL, Claas FH, Otten HG.

HLA. 2016 Sep;88(3):110-9. doi: 10.1111/tan.12860. Epub 2016 Aug 18.

PMID:
27534609
25.

Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations.

Adema AY, van Ittersum FJ, Hoenderop JG, de Borst MH, Nanayakkara PW, Ter Wee PM, Heijboer AC, Vervloet MG; NIGRAM consortium.

PLoS One. 2016 Jan 25;11(1):e0144121. doi: 10.1371/journal.pone.0144121. eCollection 2016.

26.

Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.

van Breda F, Emans ME, van der Putten K, Braam B, van Ittersum FJ, Kraaijenhagen RJ, de Borst MH, Vervloet M, Gaillard CA.

PLoS One. 2015 Jun 16;10(6):e0128994. doi: 10.1371/journal.pone.0128994. eCollection 2015.

27.

The Biobank of Nephrological Diseases in the Netherlands cohort: the String of Pearls Initiative collaboration on chronic kidney disease in the university medical centers in the Netherlands.

Navis GJ, Blankestijn PJ, Deegens J, De Fijter JW, Homan van der Heide JJ, Rabelink T, Krediet RT, Kwakernaak AJ, Laverman GD, Leunissen KM, van Paassen P, Vervloet MG, Wee PM, Wetzels JF, Zietse R, van Ittersum FJ; BIND-NL investigators.

Nephrol Dial Transplant. 2014 Jun;29(6):1145-50. doi: 10.1093/ndt/gft307. Epub 2013 Oct 22. Review.

PMID:
24151018
28.

Higher plasma levels of von Willebrand factor and C-reactive protein during a peritoneal dialysis regimen with less glucose and glucose degradation products.

le Poole CY, Schalkwijk CG, Teerlink T, Valentijn RM, Ter Wee PM, van Ittersum FJ.

Perit Dial Int. 2013 Mar-Apr;33(2):208-12. doi: 10.3747/pdi.2012.00097. No abstract available.

29.

Long-term effects of melatonin on quality of life and sleep in haemodialysis patients (Melody study): a randomized controlled trial.

Russcher M, Koch BC, Nagtegaal JE, van Ittersum FJ, Pasker-de Jong PC, Hagen EC, van Dorp WT, Gabreëls B, Wildbergh TX, van der Westerlaken MM, Gaillard CA, Ter Wee PM.

Br J Clin Pharmacol. 2013 Nov;76(5):668-79. doi: 10.1111/bcp.12093.

30.

Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on arterial compliance and distensibility in patients with mild-to-moderate chronic kidney disease.

Veringa SJ, Nanayakkara PW, van Ittersum FJ, Vegting IL, van Guldener C, Smulders YM, ter Wee PM, Stehouwer CD.

Clin Nephrol. 2012 Oct;78(4):263-72.

PMID:
22981031
31.

A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation.

le Poole CY, Welten AG, ter Wee PM, Paauw NJ, Djorai AN, Valentijn RM, Beelen RH, van den Born J, van Ittersum FJ.

Perit Dial Int. 2012 May-Jun;32(3):305-15. doi: 10.3747/pdi.2010.00115. Epub 2011 Nov 1.

32.

"NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.

le Poole CY, van Ittersum FJ, Valentijn RM, Teerlink T, Lindholm B, Ter Wee PM, Schalkwijk CG.

Perit Dial Int. 2012 Jan-Feb;32(1):45-54. doi: 10.3747/pdi.2010.00101. Epub 2011 May 31.

33.

Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.

Vervloet MG, van Ittersum FJ, Büttler RM, Heijboer AC, Blankenstein MA, ter Wee PM.

Clin J Am Soc Nephrol. 2011 Feb;6(2):383-9. doi: 10.2215/CJN.04730510. Epub 2010 Oct 28.

34.

Similar peritonitis outcome in CAPD and APD patients with dialysis modality continuation during peritonitis.

Rüger W, van Ittersum FJ, Comazzetto LF, Hoeks SE, ter Wee PM.

Perit Dial Int. 2011 Jan-Feb;31(1):39-47. doi: 10.3747/pdi.2009.00235. Epub 2010 Jun 17.

PMID:
20558813
35.

Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3 - 5 chronic kidney disease.

Nanayakkara PW, Le Poole CY, Fouque D, van Guldener C, Stehouwer CD, Smulders YM, van Ittersum FJ, Siegert CE, Drai J, Kostense PJ, ter Wee PM.

Clin Nephrol. 2009 Jul;72(1):21-30.

PMID:
19640384
36.

Conventional versus biocompatible peritoneal dialysis fluids: more questions than answers?

Farhat K, van Ittersum FJ, Ter Wee PM, Douma CE.

NDT Plus. 2008 Oct;1(Suppl 4):iv46-iv50. doi: 10.1093/ndtplus/sfn124.

37.

Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.

Nanayakkara PW, Kiefte-de Jong JC, ter Wee PM, Stehouwer CD, van Ittersum FJ, Olthof MR, Teerlink T, Twisk JW, van Guldener C, Smulders YM.

Am J Kidney Dis. 2009 Jan;53(1):41-50. doi: 10.1053/j.ajkd.2008.06.016. Epub 2008 Sep 11.

PMID:
18786751
38.

Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease.

Nanayakkara PW, Kiefte-de Jong JC, Stehouwer CD, van Ittersum FJ, Olthof MR, Kok RM, Blom HJ, van Guldener C, ter Wee PM, Smulders YM.

Nephrol Dial Transplant. 2008 Aug;23(8):2586-92. doi: 10.1093/ndt/gfn040. Epub 2008 Feb 20.

PMID:
18287179
39.

The new peritoneal dialysis solutions: friends only, or foes in part?

ter Wee PM, van Ittersum FJ.

Nat Clin Pract Nephrol. 2007 Nov;3(11):604-12. Review.

PMID:
17957197
40.

The first weeks on peritoneal dialysis: effects on clinical parameters.

Farhat K, van Ittersum FJ, Fabbrini P, ter Wee PM, Douma CE.

Adv Perit Dial. 2007;23:102-6.

PMID:
17886613
42.

Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension.

Spoelstra-de Man AM, van Ittersum FJ, Schram MT, Kamp O, van Dijk RA, Ijzerman RG, Twisk JW, Brouwer CB, Stehouwer CD.

J Hum Hypertens. 2006 Aug;20(8):599-611. Epub 2006 May 4.

PMID:
16673014
43.

New PD fluids: what studies do we need?

van Ittersum FJ, ter Wee PM.

Perit Dial Int. 2005 Sep-Oct;25(5):438-40. No abstract available.

PMID:
16178475
44.

Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious.

le Poole CY, Welten AG, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM.

Perit Dial Int. 2005 Feb;25 Suppl 3:S64-8.

PMID:
16048260
45.
46.

[From gene to disease; dopamine-beta-hydroxylase deficiency and orthostatic hypotension].

Deinum J, van den Meiracker AH, Boomsma F, van Ittersum FJ, Wevers RA, Lenders JW.

Ned Tijdschr Geneeskd. 2004 Sep 4;148(36):1771-5. Review. Dutch.

PMID:
15495941
47.

Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study.

le Poole CY, van Ittersum FJ, Weijmer MC, Valentijn RM, ter Wee PM.

Adv Perit Dial. 2004;20:170-6.

PMID:
15384821
48.

Autonomic nervous function, arterial stiffness and blood pressure in patients with Type I diabetes mellitus and normal urinary albumin excretion.

van Ittersum FJ, Schram MT, van der Heijden-Spek JJ, Van Bortel LM, Elte JW, Biemond P, Staessen JA, Donker AJ, Stehouwer CD.

J Hum Hypertens. 2004 Nov;18(11):761-8.

PMID:
15175635
49.

DBH gene variants that cause low plasma dopamine beta hydroxylase with or without a severe orthostatic syndrome.

Deinum J, Steenbergen-Spanjers GC, Jansen M, Boomsma F, Lenders JW, van Ittersum FJ, Hück N, van den Heuvel LP, Wevers RA.

J Med Genet. 2004 Apr;41(4):e38. No abstract available.

50.

Determinants of brachial artery mean 24 h pulse pressure in individuals with Type II diabetes mellitus and untreated mild hypertension.

van Dijk RA, van Ittersum FJ, Westerhof N, van Dongen EM, Kamp O, Stehouwer CD.

Clin Sci (Lond). 2002 Feb;102(2):177-86.

PMID:
11834137

Supplemental Content

Loading ...
Support Center